More recently, Hagerling et al. showed a role for LGR5 in tumor initiation in TNBC through different lineage-tracing experiments that revealed a therapeutic potential of anti-LGR5 to target LGR5 + cells in an aggressive ER-negative BC19. This evidence concerns the gene LGR5 and neoplasm.